| Variable | Study population (n = 616) | No endpoint (n = 602) | With endpoint (n = 14) | p-value |
| Medication n (%) | ||||
| ASS and/or Clopidogrel | 224 (36.4) | 218 (36.2) | 6 (42.9) | 0.609 |
| Beta-Blocker | 272 (44.2) | 269 (44.7) | 3 (21.4) | 0.083 |
| ACE Inhibitor/ARB | 341 (55.4) | 334 (55.5) | 7 (50) | 0.683 |
| Diuretics | 152 (24.7) | 149 (24.8) | 3 (21.4) | 0.776 |
| Oral Anticoagulation | 43 (7) | 42 (7) | 1 (7.1) | 0.981 |
| Vital parameters and clinical findings at admission | ||||
| RR systolic | 144.6 (±21.8) | 144.8 (±21.8) | 138.1 (±20.8) | 0.273 |
| Cardiac Insufficiency | 32 (5.2) | 31 (5.1) | 1 (7.1) | 0.740 |
| NYHA Stage n (%) | 0.236 | |||
| 0 | 287 (46.6) | 283 (47) | 4 (28.6) |
|
| I | 187 (30.4) | 183 (30.4) | 4 (28.6) |
|
| II | 120 (19.5) | 114 (18.9) | 6 (42.9) |
|
| III | 21 (3.2) | 21 (3.5) | 0 |
|
| IV | 1 (0.2) | 1 (0.2) | 0 |
|
| CCS Stage n (%) | 0.542 | |||
| 0 | 360 (58.4) | 353 (58.6) | 7 (50) |
|
| I | 189 (30.7) | 185 (30.7) | 4 (28.6) |
|
| II | 62 (10.1) | 59 (9.8) | 3 (21.4) |
|
| III | 5 (0.8) | 5 (0.8) | 0 |
|
| Revised Cardiac Risk Index | 0.035 | |||
| 0 | 421 (68.3) | 416 (69.1) | 5 (35.7) |
|
| 1 | 148 (24) | 142 (23.6) | 6 (42.9) |
|
| 2 | 39 (6.3) | 37 (6.1) | 2 (14.3) |
|
| 3 | 7 (1.1) | 6 (1) | 1 (7.1) |
|
| 4 | 1 (0.2) | 1 (0.2) | 0 |
|